Current Oncogenic Biomarkers In Lung Cancer An early diagnosis, the identification of conditions predisposing to lung cancer, and the definition of the tumor genetic profile are crucial steps to improved patient outcomes. in the present special issue, “diagnostic and predictive biomarkers in lung cancer”, these important topics are covered across fourteen peer reviewed papers. 1. introduction. lung cancer (lc) is the leading cause of cancer related mortality worldwide, responsible for 18.4% of all cancer deaths. the latest globocan database estimates that 2.2 million new lung cancer cases emerged in 2020 worldwide [].
Current Oncogenic Biomarkers In Lung Cancer Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. substantial improvements in our understanding of disease biology, application of predictive biomarkers, and refinements in treatment have led to remarkable progress in the past two decades and transformed. Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging. According to this data, lmn (lamin), vim (vimentin), tub (tubulin), and act (actin) detected with the help of aptamers lc 18, lc 17, and lc 24 are involved in cancer progression and could act as lung adenocarcinoma biomarkers [88]. go to: 9. biomarkers of different histological lung cancer types. The next sections will delineate current oncogenic biomarkers in lung cancer, reviewing the background, clinical features, detection methods, most common alterations and fda approved therapies.
Comments are closed.